Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

NCT04957615 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions

BIOLOGICAL: Nivolumab

Sponsor

M.D. Anderson Cancer Center